Trial Search Results

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

The purpose of this study is to assess the safety and tolerability of escalating doses of SD-101 in combination with localized low-dose radiation therapy (XRT) in patients with untreated low-grade B-cell lymphoma. SD-101 is an investigational Toll-like receptor ("TLR") 9 agonist.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Dynavax Technologies Corporation

Stanford Investigator(s):

Intervention(s):

  • Drug: SD-101
  • Radiation: Radiation therapy

Phase:

Phase 1/Phase 2

Eligibility


Inclusion Criteria:

   - Biopsy confirmed, untreated, low-grade B-cell lymphoma, including follicular (Grade 1,
   2, or 3A) [Harris, Swerdlow et al. 2008] or marginal, or CLL/SLL with lymph node
   involvement.

   - At least 2 sites of measurable disease per Cheson criteria (must measure at least 1.5
   cm in any diameter or 1.0 cm in the shortest diameter if one of the diameters is not ≥
   1.5 cm), one of which must be palpable and easily accessible in a low-risk site (eg,
   inguinal, axillary, cervical, subcutaneous) for intratumoral injection (denoted as
   "Lesion A" in Treatment Cycle 1) and at least one additional untreated lesion that is
   located outside the radiation field of the treated lesion (Lesion A) and is accessible
   for an FNA aspirate.

   - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1

   - Aged 18 years and older

   - Absolute neutrophil count (ANC) ≥ 1500/mm3

   - Platelet count > 100,000/µL

   - Serum creatinine (Cr) ≤ 1.5 x upper limit of normal (ULN).

   - Serum total bilirubin ≤ 1.5 x the ULN.

   - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN

   - International normalized ratio or prothrombin time (PT) ≤ 1.5 x ULN unless subject is
   receiving anticoagulant therapy and the PT or partial thromboplastin time (PTT) must
   be within the therapeutic range of the intended use of anticoagulants.

   - Activated PTT (aPTT) ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy,
   and the PT or PTT is within therapeutic range of intended use of anticoagulants.

   - Female subjects must have a negative urine or serum pregnancy test within 72 hours
   prior to taking study medication if of childbearing potential as defined in this
   protocol. Women of childbearing potential (WOCBP) must be willing to use 2 medically
   acceptable method of contraceptive from Day 1 through 120 days after the last dose of
   trial treatment. The 2 medically acceptable birth control methods can be either 2
   barrier methods or a barrier method plus a hormonal method to prevent pregnancy. The
   following are considered adequate barrier methods of contraception: diaphragm, condom
   (by the partner), cooper intrauterine device, sponge, or spermicide as per local
   regulations or guidelines. Appropriate hormonal contraceptives will include any
   registered and marketed contraceptive agent that contains an estrogen and/or a
   progestational agent (including oral, subcutaneous, intrauterine, or intramuscular
   agents).

   - Ability to understand and sign informed consent form (ICF) and comply with treatment
   protocol

Exclusion Criteria:

   - Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other
   form of immunosuppressive therapy (including immune modulators or systemic
   corticosteroids) within 7 days prior to study enrollment.

   - Positive for hepatitis B (HBsAg reactive), HCV ribonucleic acid (RNA) qualitative, or
   human immunodeficiency virus (HIV)( HIV 1/2 antibodies)

   - Diagnosis of mantle or diffuse large-cell lymphoma, Grade 3B follicular lymphoma
   [Harris, Swerdlow et al. 2008] or gastric mucosa-associated lymphoid tissue (MALT)
   lymphoma

   - Clinically significant pleural effusion

   - Active infection including cytomegalovirus

   - Pregnant or breast feeding within the projected duration of trial participation
   through 4 months after the last dose of study treatment.

   - Autoimmune disease including systemic lupus erythematosus, rheumatoid arthritis,
   multiple sclerosis, Sjӧgren's syndrome, autoimmune thrombocytopenia, history of
   uveitis, or other if clinically significant

   - Lymphoma involvement of the central nervous system

   - Received any prior therapy for lymphoma

   - Use of any investigational agent within the last 28 days

   - Serious, non-healing wound, ulcer, or bone fracture.

   - If a subject received major surgery, must have recovered adequately from the toxicity
   and/or complications from the intervention prior to enrollment.

   - Clinically significant cardiovascular disease (eg, uncontrolled hypertension,
   myocardial infarction, unstable angina), New York Heart Association (NYHA) Grade II or
   greater congestive heart failure, serious cardiac arrhythmia requiring medication
   within 1 year prior to Day -1 (Visit 1); Grade II or greater peripheral vascular
   disease at study entry

   - Any other significant medical or psychiatric condition, laboratory abnormality, or
   difficulty complying with protocol requirements that may increase the risk associated
   with study participation or study drug administration that may interfere with the
   interpretation of study results and, in the judgment of the investigator, would make
   the subject inappropriate for this study

   - History of sensitivity to any component of SD-101

   - A diagnosis of cancer within the last 3 years prior to enrollment or any known
   additional malignancy that is progressing or requires active treatment. Exceptions are
   B-cell lymphoma, basal cell carcinoma of the skin, squamous cell carcinoma of the skin
   that has undergone potentially curative therapy, and in situ cervical cancer.

   - Is taking systemic corticosteroids (more than 3 consecutive days) or other
   immunomodulators or immune suppressive medication

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting